NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, September 9, 2026, to be followed by a conference call at 8:30 a.m. Eastern Time.
Conference Call Details:
To participate in the conference call, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY Second Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13761986. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
About ODDITY
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves approximately 68 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
REX Shares ("REX") and Tuttle Capital Management ("TCM") today announce that listed options are now available on the T-REX 2X Long SpaceX Daily Target ETF (NYSE Arca: SPAX), giving traders an additional way to express tactical views on one of the most closely watched names in the public market.
SPAX is designed to deliver 200% of the daily stock price performance of Space Exploration Technologies Corporation (Nasdaq: SPCX), before fees and expenses. With options now listed, traders can use calls, puts, and multi-leg strategies alongside the fund itself to manage exposure, define risk parameters, or position around the elevated volatility that has characterized SPCX since its public debut. Options on SPAX add a layer of flexibility on top of a product that already delivers leveraged daily exposure inside a liquid, transparent ETF.
"Few names generate the kind of conviction SpaceX does, and SPAX has given traders a way to act on it," said Greg King, CEO and Founder of REX. "With listed options, they can now define risk, target a daily view, and build multi-leg strategies around that conviction.”
"Layering a listed options market on top of a 2X single-stock ETF is about as much firepower as you can hand an active trader," added Matt Tuttle, CEO and CIO of Tuttle Capital Management. "SpaceX moves, and that kind of volatility is exactly what makes options on a leveraged SpaceX product so useful."
SPAX is among a growing number of T-REX funds to gain a listed options market, reflecting rising trader demand for more precise ways to play single-stock volatility. The suite now includes over 40 leveraged and inverse single-stock ETFs, among them first-to-market 2X exposures to Robinhood (ROBN), Nvidia (NVDX), and Tesla (TSLT).
Investing in the Fund is not equivalent to investing directly in SPCX.
Options involve risk and are not suitable for all investors. Prior to buying or selling an option, investors must read a copy of the Characteristics and Risks of Standardized Options, also known as the options disclosure document (ODD). It explains the characteristics and risks of exchange traded options and is available from your broker or from The Options Clearing Corporation. Options carry the risk of losing the entire premium paid in a relatively short period, and certain strategies can expose an investor to losses that exceed the initial investment.
Investing in the fund involves significant risk and is for sophisticated investors. The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. For periods longer than a single day, the Fund will lose money if SPCX's performance is flat, and it is possible that the Fund will lose money even if SPCX's performance increases over a period longer than a single day. An investor could lose the full principal value of his/her investment within a single day if the price of SPCX falls by more than 50% in one trading day.
For full fund information, holdings, and risk disclosures, visit rexshares.com.
About T-REX
The T-REX lineup is a partnership between REX Shares and Tuttle Capital Management. T-REX is redefining single-stock ETFs with first-to-market leveraged and inverse exposures. Built to deliver 2x and -2x daily performance on some of the market's most dynamic companies, T-REX funds give traders powerful tools to express high-conviction views. From being the first to launch 2x and -2x ETFs on Tesla (TSLT) and Nvidia (NVDX), to pioneering the first leveraged 2x ETFs tied to spot Bitcoin (BTCL), T-REX continues to set the pace in ETF innovation. With more than 40 products already trading, the suite is constantly expanding to meet evolving investor demand for tactical, high-impact exposures. For more information, visit rexshares.com.
About REX Shares
REX Shares offers a suite of exchange-traded products built for both active traders and long-term investors, spanning income, leveraged, thematic, and crypto strategies. Whether making short-term trades, generating income from volatility, or investing in digital assets and emerging themes like drones, REX empowers investors to act on strong market views. For more information, please visit rexshares.com.
About Tuttle Capital Management
Tuttle Capital Management is a leader in thematic and actively managed ETFs, leveraging an agile investment approach to align with market trends. Please visit www.tuttlecap.com for more information.
This ETF does not invest directly in the referenced asset and has a higher degree of risk since it is seeking to track a single stock or asset.
A link to the Fund's prospectus can be found here. Click here for fund holdings.
Investors should consider the investment objectives, risk, charges, and expenses carefully before investing. For a prospectus or summary prospectus with this and other information about the T-REX ETFs please call 1-844-802-4004 or visit our website at rexshares.com. Read the prospectus and summary prospectus carefully before investing.
There is no guarantee that the Fund will achieve its investment objective. Investing involves risk, including possible loss of principal.
Important Risks
Investing in a REX Shares ETF may be more volatile than investing in broadly diversified funds. The use of leverage by a Fund increases the risk to the Fund. The REX Shares ETFs are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk, consequences of seeking daily leveraged, or daily inverse leveraged, investment results and intend to actively monitor and manage their investment.
An investment in the Fund entails risk. The Fund may not achieve its leveraged investment objective and there is a risk that you could lose all of your money invested in the Fund. The Fund is not a complete investment program. In addition, the Fund presents risks not traditionally associated with other mutual funds and ETFs. It is important that investors closely review all of the risks listed below and understand them before making an investment in the Fund.
Options Risk. The Fund and its shares may be the reference asset for listed options. Options are complex instruments and may be more volatile than the underlying shares. The use of options may involve risks different from, or greater than, the risks associated with investing directly in the Fund, including the risk that an option may expire worthless and the risk of significant or total loss of the premium paid.
Effects of Compounding and Market Volatility Risk. The Fund has a daily leveraged investment objective and the Fund's performance for periods greater than a trading day will be the result of each day's returns compounded over the period, which is very likely to differ from 200% of the underlying's performance, before fees and expenses. Compounding affects all investments, but has a more significant impact on funds that are leveraged and that rebalance daily and becomes more pronounced as volatility and holding periods increase.
Leverage Risk. The Fund obtains investment exposure in excess of its net assets by utilizing leverage and may lose more money in market conditions that are adverse to its investment objective than a fund that does not utilize leverage. An investment in the Fund is exposed to the risk that a decline in the daily performance of the underlying stock will be magnified. This means that an investment in the Fund will be reduced by an amount equal to 2% for every 1% daily decline in the underlying, not including the costs of financing leverage and other operating expenses, which would further reduce its value.
SpaceX Investing Risk. SpaceX is a commercial space transportation and aerospace technology company whose business model is dependent on the successful development, launch and operation of complex space systems, including launch vehicles, spacecraft and satellite constellations.
Liquidity Risk. Holdings of the Fund may be difficult to buy or sell or may be illiquid, particularly during times of market turmoil. Illiquid securities may be difficult to value, especially in changing or volatile markets.
Non-Diversification Risk. The Fund is classified as "non-diversified" under the Investment Company Act of 1940, as amended. This means it has the ability to invest a relatively high percentage of its assets in the securities of a small number of issuers or in financial instruments with a single counterparty or a few counterparties.
Distributor: Foreside Fund Services, LLC, member FINRA, not affiliated with REX Shares or the Funds' investment advisor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260616940253/en/
Oddity Tech is downgraded from buy to hold due to unresolved customer acquisition cost headwinds and weak first-order growth. Q1 2026 revenue declined 26% y/y, with first orders down ~50% and margins deteriorating; Q2 guidance suggests continued revenue contraction. The investment thesis now hinges on whether CPA normalization is temporary or structural, as elevated CPA undermines the core acquisition engine.
New York, New York--(Newsfile Corp. - May 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296710
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
San Francisco, California--(Newsfile Corp. - May 9, 2026) - Hagens Berman, a global shareholder rights law firm, updates investors in ODDITY Tech Ltd. (NASDAQ: ODD) regarding the pending securities class action lawsuit following a massive 49% stock collapse. The firm reminds investors that the deadline to move for Lead Plaintiff is May 11, 2026.
SUBMIT YOUR LOSSES TO HAGENS BERMAN NOW
The ODD Securities Class Action: When Did ODDITY Know About the Dislocation?
The lawsuit against ODDITY, a consumer tech company that uses AI to sell beauty products, alleges the company misrepresented the stability of its digital operating model. While ODDITY repeatedly assured investors that its AI platform would sustain high growth and attractive margins, it allegedly failed to disclose a critical disruption.
On February 25, 2026, ODDITY admitted it had experienced a dislocation in its primary advertising account due to algorithm changes by its largest partner. This change diverted ODDITY's ads to lower-quality auctions at abnormally high costs, causing:
Spiking Customer Acquisition Costs (CAC): Advertising efficiency plummeted, directly impacting margins.Severe Revenue Contraction: The company projected a staggering 30% year-over-year revenue decline for Q1 2026.Delayed Disclosure: During an earnings call, management admitted they "observed that something was different in the second half of 2025," yet they continued to issue optimistic growth guidance as late as November 2025.Wall Street Reaction and Market Impact
The disclosure triggered a massive selloff. ODDITY's shares fell $14.28 per share, or nearly 50%, to close at $14.74 on February 25, 2026, wiping out more than $600 million in market capitalization. In the wake of this news, major Wall Street firms, including JPMorgan and Bank of America, cut their ratings on the stock.
"We are investigating whether ODDITY knowingly issued false statements during the second half of 2025 while privately watching its primary growth engine fail," said Reed Kathrein, the Hagens Berman partner leading the investigation.
Lead Plaintiff Deadline: May 11, 2026
Investors who purchased ODDITY securities between February 26, 2025, and February 24, 2026, and suffered losses, have until May 11, 2026, to seek a lead role in the litigation.
Report Your ODD Investment Losses Now Visit: www.hbsslaw.com/cases/oddity Email: [email protected] Call 844-916-0895Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
# # #
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296656
Source: Hagens Berman Sobol Shapiro LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Oddity To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Oddity between February 26, 2025 and February 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - May 9, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Oddity Tech Ltd. ("Oddity" or the "Company") (NASDAQ: ODD) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (ii) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (iii) accordingly, Defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On February 25, 2026, Oddity reported its full year 2025 financial results, disclosing that Oddity "experienced a dislocation in our account with our largest advertising partner that we believe was driven by algorithm changes which diverted us to lower quality auctions at abnormally high costs. This is resulting in significant increases in new user acquisition costs that are not correlated with the market or our historical experience."
On this news, the price of Oddity stock fell more than 49%.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Oddity's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Oddity Tech class action, go to www.faruqilaw.com/ODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296493
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - May 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296711
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
SAN FRANCISCO, May 10, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a global shareholder rights law firm, updates investors in ODDITY Tech Ltd. (NASDAQ: ODD) regarding the pending securities class action lawsuit following a massive 49% stock collapse. The firm reminds investors that the deadline to move for Lead Plaintiff is May 11, 2026.
SUBMIT YOUR LOSSES TO HAGENS BERMAN NOW
The ODD Securities Class Action: When Did ODDITY Know About the Dislocation?
The lawsuit against ODDITY, a consumer tech company that uses AI to sell beauty products, alleges the company misrepresented the stability of its digital operating model. While ODDITY repeatedly assured investors that its AI platform would sustain high growth and attractive margins, it allegedly failed to disclose a critical disruption.
On February 25, 2026, ODDITY admitted it had experienced a dislocation in its primary advertising account due to algorithm changes by its largest partner. This change diverted ODDITY’s ads to lower-quality auctions at abnormally high costs, causing:
Spiking Customer Acquisition Costs (CAC): Advertising efficiency plummeted, directly impacting margins.Severe Revenue Contraction: The company projected a staggering 30% year-over-year revenue decline for Q1 2026.Delayed Disclosure: During an earnings call, management admitted they "observed that something was different in the second half of 2025," yet they continued to issue optimistic growth guidance as late as November 2025.
Wall Street Reaction and Market Impact
The disclosure triggered a massive selloff. ODDITY’s shares fell $14.28 per share, or nearly 50%, to close at $14.74 on February 25, 2026, wiping out more than $600 million in market capitalization. In the wake of this news, major Wall Street firms, including JPMorgan and Bank of America, cut their ratings on the stock.
“We are investigating whether ODDITY knowingly issued false statements during the second half of 2025 while privately watching its primary growth engine fail,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
Lead Plaintiff Deadline: May 11, 2026
Investors who purchased ODDITY securities between February 26, 2025, and February 24, 2026, and suffered losses, have until May 11, 2026, to seek a lead role in the litigation.
Report Your ODD Investment Losses NowVisit: www.hbsslaw.com/cases/oddityEmail: [email protected] 844-916-0895 Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the “Class Period”), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity’s largest advertising partner, Oddity’s advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity’s customer acquisition costs, thereby negatively impacting Oddity’s business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity’s digital operating model and/or market position; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
New York, New York--(Newsfile Corp. - May 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ODDITY Tech Ltd. (NASDAQ: ODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Oddity securities between February 26, 2025 and February 24, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ODD.
Oddity Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse facts concerning the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose that:
following an algorithm change by the Company's largest advertising partner, the Company's advertisements were diverted to lower-quality auctions at abnormally high costs; as a result, the Company's customer acquisition costs increased significantly, negatively impacting its business and financial prospects; Defendants therefore overstated the strength, stability, and sustainability of the Company's digital operating model and market position; and as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Oddity Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ODD, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Oddity you have until May 11, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Oddity Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Oddity Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295575
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES, May 11, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Oddity Tech Ltd. (“Oddity” or “the Company”) (NASDAQ: ODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company’s securities between February 26, 2025 and February 24, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before May 11, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Oddity’s advertisements were diverted to poor quality auctions at high costs due to an algorithm change by one of its largest ad partners. The Company’s customer acquisition costs increased significantly due to this change, harming its business. The Company overstates the strength of its operating model. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Oddity, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
NEW YORK--(BUSINESS WIRE)---- $ODD #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Oddity Tech Ltd. (“Oddity” or the “Company”) (NASDAQ: ODD) and reminds investors of the May 11, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has reco.
New York, New York--(Newsfile Corp. - May 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ODDITY Tech Ltd. (NASDAQ: ODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Oddity securities between February 26, 2025 and February 24, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ODD.
Oddity Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse facts concerning the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose that:
following an algorithm change by the Company's largest advertising partner, the Company's advertisements were diverted to lower-quality auctions at abnormally high costs; as a result, the Company's customer acquisition costs increased significantly, negatively impacting its business and financial prospects; Defendants therefore overstated the strength, stability, and sustainability of the Company's digital operating model and market position; and as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Oddity Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ODD, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Oddity you have until May 11, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Oddity Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Oddity Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295576
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - May 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), of the important May 11, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296922
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
SAN FRANCISCO, May 11, 2026 /PRNewswire/ -- Hagens Berman, a global shareholder rights law firm, updates investors in ODDITY Tech Ltd. (NASDAQ: ODD) regarding the pending securities class action lawsuit following a massive 49% stock collapse.
, /PRNewswire/ -- A securities class action lawsuit has been filed against ODDITY Tech. Ltd. (NASDAQ: ODD), seeking to represent investors who purchased ODDITY securities between February 26, 2025 and February 24, 2026.
The lawsuit follows the 49% decline in the price of ODDITY American Depositary Shares on February 25, 2026. The selloff, which wiped out over $600 million dollars of the company's market capitalization, was triggered by the company's announcement that it expects a whopping 30% year-over-year decline in its Q1 2026 revenue.
The development and severe market reaction have prompted national shareholders rights firm Hagens Berman to investigate claims that ODDITY violated the federal securities laws.
The firm urges investors in ODDITY who suffered significant losses to submit your losses now. The firm also encourages witnesses who may be able to assist in the investigation to contact its attorneys.
Class Period: Feb. 26, 2025 – Feb. 24, 2026
Lead Plaintiff Deadline: May 11, 2026
Visit: www.hbsslaw.com/investor-fraud/odd
Contact the Firm Now: [email protected]
844-916-0895
ODDITY Tech. Ltd. (ODD) Securities Class Action:
The lawsuit is focused on ODDITY's repeated touting of its AI-driven online platform, which the company assured investors would "sustain our high-growth and attractive margin profile[.]"
The complaint alleges that ODDITY made false and misleading statements while failing to disclose crucial information to investors, including an algorithm change by the company's largest advertising partner which resulted in the diversion of ODDITY's advertisements to lower quality auctions at abnormally high costs.
This, in turn, significantly increased ODDITY's customer acquisition costs and negatively affected the company's business and financial prospects.
In addition, the complaint alleges, the foregoing resulted in the company's overstating the overall strength, stability, and sustainability of ODDITY's digital operating model.
Investors' expectations were dashed on February 25, 2026, when ODDITY announced its Q4 and FY 2025 financial results and revealed that "we experienced a dislocation in our account with our largest advertising partner that we believe was driven by algorithm changes which diverted us to lower quality auctions at abnormally high costs" that drove new user acquisition costs significantly higher.
During the related earnings call, an analyst pressed management about when ODDITY first knew of the dislocation, but management would only say that they had "observed that something was different in the second half of 2025" – that is, without acknowledging when the issue actually started.
As concerning, ODDITY quantified the effects of the dislocation, saying that Q1 2026 revenue would decline 30% year-over-year.
"We're investigating when ODDITY first knew of the dislocation issue and whether it may have intentionally misled investors about the true strength of its AI growth-driver," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in ODDITY and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »
If you'd like more information and answers to additional frequently asked questions about the ODDITY case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding ODDITY should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (“ODDITY”) (NASDAQ: ODD), today announced that it will release its first quarter 2026 financial results before the market open on Tuesday, June 2, 2026, to be followed by a conference call at 8:30 a.m. Eastern Time.
Conference Call Details:
To participate in the conference call, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY First Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13760709. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
About ODDITY
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves approximately 68 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
Oddity's 2025 base still looks strong, but Q1 will test my ad reset contrarian thesis. The real issue is whether Try Before You Buy can still scale through paid social. Fortunately, they have a relatively liquid balance sheet, and the increased buyback could help support their stock price going forward.
First quarter net revenue of $197.9 million, down approximately 26% year-over-yearFirst quarter adjusted EBITDA of $(7.0) millionFirst quarter net loss of $(21.4) million and first quarter adjusted net loss of $(9.8) millionStrong liquidity position including cash, cash equivalents and investments of $667.4 million, and aggregate credit facilities of $350 million which remain undrawn NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the first quarter ended March 31, 2026.
“We continue to implement our recovery plan to address the account dislocation with our largest advertising partner and we remain hopeful that we are on track for normalization in the second half of this year,” said Oran Holtzman, ODDITY co-founder and CEO. “For many years, our CPA was very stable, with only gradual increases aligned with our industry. In Q1 2026, we saw a severe step-function discontinuity, comparing to historical first quarters, with CPA in some cases reaching levels 2x higher than what we expected. While we continue to navigate this dislocation, we have been working closely with our advertising partner on remediation and we are encouraged by an improvement in IL MAKIAGE CPA this May, which declined an estimated -28% sequentially from April.”
Media Costs
ODDITY is providing additional data on IL MAKIAGE CPA with our largest advertising partner for H1 2022 through May of H1 2026, as the first half is historically the period in which we acquire the majority of our annual new users. We believe this data supports the view that the CPA dislocation is technical in nature, rather than driven by brand health or market saturation.
Prior to 2026, IL MAKIAGE 1H CPA growth was very stable, with yearly increases correlated with our industry.The increase in 2026 is sudden, indicating a dramatic break rather than steady deterioration over time.The breakdown occurred in different markets simultaneously. US, Canada, UK, Australia, Israel — markets with different longevity and saturation levels.A driver of the break is spiking bounce rates. This shows in our view that the issue is with lower quality audiences being served our ads by the algorithm. IL MAKIAGE CPA Index with Largest Advertising Partner, Internal Attribution System
Half-Year
CPA INDEX
YOY % CHG
H122
1.0
H123
1.2
16
%
H124
1.3
14
%
H125
1.5
15
%
H1 through May 26
2.8
83
%
First Quarter 2026 Summary
ODDITY achieved key objectives during the first quarter, including:
Exceeded our first quarter revenue outlook issued February 25, 2026 of an approximately 30% decline.Positive inflection in IL MAKIAGE CPA’s trend in May, reflecting progress resetting our ad account signals.Remediation work in IL MAKIAGE Try Before You Buy, and a shift of 40% of acquisition revenue out of Try Before You Buy and into Buy.A strong start for our newest brand, METHODIQ, which remains on track to deliver year 1 results in-line with those of SpoiledChild.Ongoing development and expansion of the ODDITY Labs molecule discovery platform.Strong liquidity position including cash, cash equivalents and investments of $667.4 million, and aggregate credit facilities of $350 million which remain undrawn. “We are pleased with the progress we see in our remediation work and with our ability to deliver first quarter revenue above our guidance,” said Lindsay Drucker Mann, ODDITY Global CFO. “The CPA dislocation led to a sharp decline in first orders during the quarter, and the loss of these first orders will negatively impact our repeat business across the year. We therefore expect Q2 net revenue will decline between 25 and 30% year-over-year, and hope to see sequential improvement in the second half of 2026.”
Profitability Drivers
Adjusted EBITDA was materially negatively impacted by higher CPA and ODDITY’s decision to spend on acquisition during the quarter, in an effort to remedy the account dislocation. This led to significantly lower revenue generated on like for like media spend. Reduced media efficiency coupled with continued investment in growth initiatives drove meaningful operating expense deleverage.
Gross margin compression in the period was driven in part by product and brand mix and a low single digit decline in average order value (AOV). ODDITY’s remediation activity during the quarter, which included running various tests to try and isolate the dislocation in its advertising account, negatively impacted Q1 margins.
Share Buyback Program
In March 2026, ODDITY’s Board of Directors approved a share buyback program authorizing the repurchase of up to $200 million of the Company’s Class A ordinary shares. The new authorization expires on March 31, 2029 or upon full deployment of the allocated funds, subject to any future modifications by the Board.
ODDITY repurchased approximately 6.1 million Class A ordinary shares during the first quarter for approximately $82.3 million, reducing Class A ordinary shares outstanding by approximately 10.6%. ODDITY exited the first quarter with approximately $167.3 million remaining under the authorization, subject to market conditions, legal and regulatory constraints.
First Quarter Fiscal 2026 Financial Highlights:
Results for the first quarter ended March 31, 2026 are presented below in comparison to the first quarter ended March 31, 2025.
Net revenue was $197.9 million compared to $268.1 million in the first quarter of 2025, a decrease of 26%.Gross profit was $138.0 million compared to $200.8 million in the first quarter of 2025; gross margin was 69.7% compared to 74.9% in the first quarter of 2025.Net loss was $(21.4) million compared to net income of $37.8 million in the first quarter of 2025.Adjusted net loss was $(9.8) million compared to adjusted net income of $41.8 million in the first quarter of 2025.Adjusted EBITDA was $(7.0) million compared to $52.4 million in the first quarter of 2025.Diluted loss per share was $(0.38) for the first quarter of 2026 compared to diluted earnings per share of $0.63 in the first quarter of 2025.Adjusted diluted loss per share was $(0.17) for the first quarter of 2026 compared to adjusted diluted earnings per share of $0.69 in the first quarter of 2025. Financial Outlook:
For the second quarter of 2026, ODDITY expects net revenue to decline between 25 and 30% year-over-year. ODDITY expects Adjusted EBITDA will be between $8 and $10 million.
For the full year 2026, ODDITY expects Adjusted EBITDA to be positive.
Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net (loss) income, Adjusted net (loss) income margin, Adjusted diluted (loss) earnings per share, and free cash flow are non-GAAP financial measures. Please see the sections titled “Non-GAAP Financial Measures” and “Reconciliations of GAAP to Non-GAAP Measures” below for more information regarding ODDITY’s use of non-GAAP financial measures and reconciliations to the most directly comparable GAAP measures. ODDITY has not provided a quantitative reconciliation of its Adjusted EBITDA outlook to the corresponding net income measure because the quantification of certain items included in the calculation of GAAP net income cannot be calculated or predicted at this time without unreasonable efforts. ODDITY is unable to address the probable significance of the unavailable reconciling items, which could have a potentially unpredictable, and potentially significant, impact on its future GAAP financial results.
The financial outlook figures presented above are forward-looking statements that are subject to a variety of assumptions and estimates. Actual results may differ materially from ODDITY’s financial outlook as a result of, among other things, the factors described under “Forward-Looking Statements” below.
Conference Call Details:
A conference call to discuss ODDITY’s Q1 2026 financial and business results and outlook is scheduled for today, June 2, 2026, at 8:30 a.m. ET. To participate, please dial 1-877-407-9208 (US) or 1-201-493-6784 (international). To access the call, please reference the company name and call title: ODDITY First Quarter 2026 Earnings Call. A webcast of the call will be accessible on the Investors section of ODDITY’s website at https://investors.oddity.com. A recording will be available shortly after the conclusion of the call. To access the replay, please dial 1-844-512-2921 (US) or 1-412-317-6671 (international). The access code for the replay is 13760709. An archive of the webcast will be available on the Investors section of ODDITY’s website for seven days following the call.
Non-GAAP Financial Measures:
In addition to the GAAP financial measures set forth in this press release, ODDITY has included the following non-GAAP financial measures: Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net (loss) income, Adjusted net (loss) income margin, Adjusted diluted (loss) earnings per share and free cash flow. ODDITY believes these non-GAAP financial measures provide useful supplemental information to management and investors to help evaluate ODDITY’s business, measure its performance, identify trends, prepare financial projections and make business decisions.
ODDITY defines “Adjusted EBITDA” as net (loss) income before financial income, net, taxes on income, and depreciation and amortization as further adjusted to exclude share-based compensation expense and non-recurring items. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by net revenue. ODDITY believes Adjusted EBITDA and Adjusted EBITDA margin are useful for financial and operational decision-making and as a means to evaluate period-to-period comparisons. By excluding certain items that may not be indicative of its recurring core operating results, ODDITY believes that Adjusted EBITDA and Adjusted EBITDA margin provide meaningful supplemental information regarding its performance. In addition, Adjusted EBITDA and Adjusted EBITDA margin are widely used by investors and securities analysts to measure a company’s operating performance without regard to items such as depreciation and amortization, interest expense, and interest income, which can vary substantially from company to company depending on their financing and capital structures and the method by which their assets were acquired.
ODDITY defines “Adjusted net (loss) income” as net (loss) income adjusted for the impact of share-based compensation, non-recurring items, one-time tax gains/losses and the tax effect of non-GAAP adjustments and “Adjusted net (loss) income margin” as Adjusted net (loss) income divided by net revenue. In addition, ODDITY defines “Adjusted diluted (loss) earnings per share” as Adjusted net (loss) income divided by diluted shares outstanding. ODDITY believes the presentations of Adjusted net (loss) income, Adjusted net (loss) income margin, and Adjusted diluted (loss) earnings per share are useful because they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry. Further, ODDITY believes these measures are helpful in highlighting trends in our operating results, because they exclude the impact of items that are outside the control of management or not reflective of our ongoing operations and performance.
ODDITY defines “free cash flow” as net cash (used in) provided by operating activities less purchase of property and equipment.
ODDITY’s non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, its financial results prepared in accordance with U.S. GAAP. Other companies, including companies in our industry, may calculate these measures differently or not at all, which reduces their usefulness as comparative measures.
Reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures are included with the financial tables at the end of this release under the heading “Reconciliations of GAAP to Non-GAAP Measures.”
Forward-Looking Statements:
Certain statements in this press release may constitute “forward-looking” statements and information, within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events. In some cases, these forward-looking statements can be identified by words or phrases such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “hope,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,” “will,” “seek,” or similar words. The absence of these words does not mean that a statement is not forward-looking. These forward-looking statements address various matters, including ODDITY’s business strategy, market opportunity, ability to deliver superior products and experiences, ability to remedy the dislocation in our customer acquisition costs, potential long-term success and ODDITY’s outlook for the second quarter of 2026 and the full year ending December 31, 2026. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the following: our ability to maintain the value of our brands; our ability to anticipate and respond to market trends and changes in consumer preferences; our ability to cost-effectively attract new customers (including by responding effectively to changes to algorithm-based bidding systems on key advertising platforms), retain existing customers and maintain or increase sales to those customers; our ability to maintain a strong base of engaged customers and content creators; the loss of suppliers or shortages or disruptions in the supply of raw materials or finished products; our ability to accurately forecast customer demand, manage our inventory, and plan for future expenses; our future rate of growth; competition; the fluctuating cost of raw materials; the illegal distribution and sale by third parties of counterfeit versions of our products or the unauthorized diversion by third parties of our products; changes in, or disruptions to, our shipping arrangements; our ability to manage our growth effectively; a general economic downturn or sudden disruption in business conditions; our ability to successfully introduce and effectively market new brands, or develop and introduce new, innovative, and updated products; foreign currency fluctuations; product returns; our ability to execute on our business strategy; our ability to maintain a high level of customer satisfaction; our ability to comply with and adapt to changes in laws and regulatory requirements applicable to our business, including with respect to regulation of the internet and e-commerce, evolving AI-technology related laws, tax laws, the anti-corruption, trade compliance, anti-money laundering, and terror finance and economic sanctions laws and regulations, consumer protection laws, and data privacy and security laws; failure of our products to comply with quality standards and risks related to product liability claims; trade restrictions; existing and potential tariffs; any data breach or other security incident of our information technology systems, or those of our third-party service providers or cyberattacks; risks related to online transactions and payment methods; any failure to obtain, maintain, protect, defend, or enforce our intellectual property rights; conditions in Israel and the Middle East generally, including as a result of geopolitical conflict; the concentration of our voting power as a result of our dual class structure; our status as a foreign private issuer; and other risk factors set forth in the section titled “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 17, 2026, and other documents filed with or furnished to the SEC. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Except as required by applicable law, we undertake no obligation to update or revise publicly any forward-looking statements.
About ODDITY:
ODDITY is a consumer tech company that builds and scales digital-first brands to disrupt the offline-dominated beauty and wellness industries. The company serves approximately 68 million users with its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. ODDITY owns IL MAKIAGE, SpoiledChild and METHODIQ. The company operates with business headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston.
Weighted-average number of shares – basic (thousands)
56,317
56,003
Weighted-average number of shares – diluted (thousands)
56,317
60,322
Basic (loss) earnings per share
$
(0.38
)
$
0.68
Diluted (loss) earnings per share
$
(0.38
)
$
0.63
ODDITY TECH LTD.
CONSOLIDATED BALANCE SHEETS
U.S. dollar in thousands
March 31,
December 31,
2026
2025
(Unaudited)
(Audited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
278,597
$
402,209
Marketable securities
17,113
11,170
Trade receivables
23,313
16,902
Inventories
147,976
135,181
Prepaid expenses and other current assets
33,089
36,336
Total current assets
500,088
601,798
LONG-TERM ASSETS:
Marketable securities
371,626
362,571
Property, plant and equipment, net
9,986
10,864
Deferred tax asset, net
30,299
27,693
Intangible assets, net
46,141
43,582
Goodwill
64,904
64,904
Operating lease right-of-use assets
22,701
22,311
Other assets
4,082
4,069
Total long-term assets
549,739
535,994
Total assets
$
1,049,827
$
1,137,792
ODDITY TECH LTD.
CONSOLIDATED BALANCE SHEETS
U.S. dollar in thousands
March 31,
December 31,
2026
2025
(Unaudited)
(Audited)
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables
$
65,252
$
75,957
Other accounts payable and accrued expenses
51,374
32,869
Operating lease liabilities, current
6,537
6,002
Total current liabilities
123,163
114,828
LONG-TERM LIABILITIES:
Operating lease liabilities, non-current
17,260
17,463
Exchangeable Note
585,222
584,368
Other long-term liabilities
25,272
24,638
Total liabilities
750,917
741,297
SHAREHOLDERS’ EQUITY:
Class A Ordinary shares
13
15
Class B Ordinary shares
3
3
Additional paid-in capital
4,230
77,571
Accumulated other comprehensive income
2,011
4,892
Retained earnings
292,653
314,014
Total shareholders’ equity
298,910
396,495
Total liabilities and shareholders’ equity
$
1,049,827
$
1,137,792
ODDITY TECH LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollar in thousands
Three months ended March 31,
2026
2025
(Unaudited)
Cash flows from operating activities:
Net (loss) income
$
(21,361
)
$
37,831
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization
4,269
2,655
Share-based compensation
8,101
7,084
Deferred income taxes
(1,803
)
(302
)
Amortization of debt issuance costs
854
—
Change in trade receivables
(6,411
)
(4,289
)
Change in prepaid expenses and other receivables
2,772
(4,631
)
Change in inventories
(12,795
)
3,554
Change in trade payables
(10,704
)
41,642
Change in other accounts payable and accrued expenses
17,330
4,903
Change in operating lease right-of-use assets
1,943
1,969
Change in operating lease liability
(2,002
)
(2,049
)
Other
(427
)
(31
)
Net cash (used in) provided by operating activities
$
(20,234
)
$
88,336
Cash flows from investing activities:
Purchase of property, plant and equipment
(858
)
(1,002
)
Capitalization of software development costs and investment in other intangible assets
(4,197
)
(1,739
)
Investment in marketable securities, net
(18,435
)
(1,069
)
Other investing activities
—
(151
)
Net cash used in investing activities
(23,490
)
(3,961
)
Cash flows from financing activities:
Proceeds from exercise of options
13
1,931
Repurchase and retirement of ordinary shares
(80,055
)
—
Net cash (used in) provided by financing activities
(80,042
)
1,931
Effect of exchange rate fluctuations on cash and cash equivalents
106
284
Net (decrease) increase in cash, cash equivalents and restricted cash
(123,660
)
86,590
Cash, cash equivalents and restricted cash at the beginning of the period
402,279
50,347
Cash, cash equivalents and restricted cash at the end of the period
$
278,619
$
136,937
ODDITY TECH LTD.
Reconciliation of GAAP to Non-GAAP Measures
U.S. dollar in thousands (except per share data)
Three months ended
March 31,
2026
2025
(Unaudited)
Reconciliation of Net (Loss) Income and Adjusted EBITDA
Net (loss) income
$
(21,361
)
$
37,831
Financial income, net
(5,306
)
(2,647
)
Taxes on income
1,177
7,481
Depreciation and amortization
4,269
2,655
Share-based compensation
8,101
7,084
Other adjustments1
6,084
—
Adjusted EBITDA
$
(7,036
)
$
52,404
Reconciliation of Net (Loss) Income and Adjusted Net (Loss) Income
Net (loss) income
$
(21,361
)
$
37,831
Share-based compensation
8,101
7,084
Other adjustments1
6,084
—
Tax adjustments2
(2,608
)
(3,106
)
Adjusted net (loss) income
$
(9,784
)
$
41,809
¹ Represents costs of certain legal matters and employee actions outside the ordinary course of business.
2 Represents the tax impact of (a) the reconciling items above and (b) in the first quarter of 2025, other discrete tax items.
Three months ended
March 31,
2026
2025
(Unaudited)
Diluted (loss) earnings per share
$
(0.38
)
$
0.63
Adjusted diluted (loss) earnings per share
$
(0.17
)
$
0.69
Reconciliation of net cash (used in) provided by operating activities to free cash flow Three months ended
March 31,
2026
2025
(Unaudited)
Net cash (used in) provided by operating activities
$
(20,234
)
$
88,336
Purchase of property and equipment
(858
)
(1,002
)
Free cash flow
$
(21,092
)
$
87,334
ODDITY TECH LTD.
Supplemental Financial Information
U.S. dollar in thousands
Cash, cash equivalents, and investments
March 31,
December 31,
2026
2025
(Unaudited)
(Audited)
Cash, restricted cash, and cash equivalents
$
278,619
$
402,279
Marketable securities
388,739
373,741
Total cash and investments
$
667,358
$
776,020
Net revenue by sales channel Three months ended
March 31,
2026
2025
(Unaudited)
Online direct-to-consumer
$
193,055
$
261,053
Percent of net revenue
98
%
97
%
Other (Israel retail, marketing affiliates)
$
4,885
$
7,023
Percent of net revenue
2
%
3
%
Net Revenue
$
197,940
$
268,076
Note: ODDITY does not sell to resellers or distributors. Online direct-to-consumer revenues are generated directly by ODDITY through its online platform only (i.e., ILMAKIAGE.com, SpoiledChild.com, and METHODIQ.com). All revenue in Israel, including revenue generated in stores, online, and from beauty academies, is included in Other.
Oddity Tech (ODD - Free Report) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.69 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -363.22%. A quarter ago, it was expected that this online retailer of cosmetics and beauty products would post earnings of $0.14 per share when it actually produced earnings of $0.2, delivering a surprise of +42.86%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Oddity Tech, which belongs to the Zacks Internet - Software industry, posted revenues of $197.94 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 5.48%. This compares to year-ago revenues of $268.08 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Oddity Tech shares have lost about 65.2% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Oddity Tech?While Oddity Tech has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Oddity Tech was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.41 on $195.93 million in revenues for the coming quarter and $0.75 on $682.54 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Guidewire Software (GWRE - Free Report) , is yet to report results for the quarter ended April 2026. The results are expected to be released on June 4.
This provider of software to the insurance industry is expected to post quarterly earnings of $0.79 per share in its upcoming report, which represents a year-over-year change of -10.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Guidewire Software's revenues are expected to be $356.01 million, up 21.3% from the year-ago quarter.
Oddity Tech (ODD 3.19%) stock is getting hit with a big post-earnings sell-off in Tuesday's trading. The beauty industry software analytics company's share price was down 31.1% as of 2:10 p.m. ET.
Oddity reported its first-quarter results before the market opened today, and performance for the period was mixed. In addition to a wider-than-expected loss in the period, management's commentary and forward guidance were not encouraging. The stock is now down 87% over the last year.
Image source: Getty Images.
Oddity's Q1 report wasn't encouraging Oddity reported a non-GAAP (adjusted) loss of $0.17 per share in the first quarter, which was far worse than the average analyst estimate's call for a break-even quarter. While the company's revenue of $197.9 million in the period beat the average analyst estimate by roughly $10 million, sales still fell 26.2% year over year in the quarter.
Today's Change
(
-3.19
%) $
-0.35
Current Price
$
10.62
What's next for Oddity? For the current quarter, Oddity expects year-over-year sales to be down between 25% and 30%. Meanwhile, the company expects adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to be between $8 million and $10 million for the quarter and also guided for positive adjusted EBITDA for the year. Oddity's sales declines aren't moderating to the extent that investors had hoped, and a big margins miss in Q1 and soft forward guidance aren't inspiring confidence.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Upcoming presentations at ENDO 2026 highlight Lundbeck's Focused Innovator strategy and continued expansion into rare neuroendocrine diseases with high unmet medical needsThe scientific program showcases Lundbeck's investigational neurohormonal and neuroimmunological targeted therapeutic candidates, asedebart and Lu AG22515, respectively Preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody in Cushing's disease (CD), demonstrate Lundbeck's biomarker-supported approach to evaluating novel therapeutic mechanisms in rare endocrine disordersPreclinical characterization of the CD40L blocker Lu AG22515 will be shared as well as data from a patient study in thyroid eye disease (TED,) reflecting exploratory studies of CD40L modulation in autoimmune disease biology, with potential relevance to neuroinflammation implicated in several neurological and endocrine diseases, /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that new data will be presented at the 2026 Endocrine Society's Annual Meeting (ENDO), taking place June 13–16 in Chicago, Illinois, U.S. Lundbeck will present preliminary Phase II data for asedebart (Lu AG13909) in CD, reflecting Lundbeck's expansion into neuroendocrine diseases. In addition, preclinical and Phase Ib clinical exploratory findings on Lu AG22515 in patients with TED will be shared, providing insights into the broader therapeutic potential of CD40L pathway modulation across inflammatory and immunological disorders.
"Lundbeck's presence at ENDO 2026 reflects how we have expanded upon our neuroscience heritage in recent years. This involves pursuing biological drug targets within hormonal and immunological signaling pathways that offer the potential to deliver highly differentiated therapeutics for neurological and neuroendocrinology indications with high medical unmet need," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. "Through this approach, we have made significant progress across our rare disease programs, enabling decisive, biomarker-supported patient studies that facilitate early development decisions, as exemplified by our ENDO 2026 scientific program."
Asedebart data provide insight into ACTH neutralization in Cushing's disease
Among the highlights are preliminary Phase II data for asedebart, an investigational anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, being evaluated in adults with CD.
CD is a rare neuroendocrine disorder typically caused by an ACTH-secreting pituitary adenoma, leading to chronic excess cortisol production and substantial physical and neuropsychiatric burden.1,2 While surgery is the standard first-line treatment, many patients experience persistent or recurrent disease despite available pharmacologic options, and significant unmet need remains.
The Phase II data being presented include impact on urinary free cortisol (UFC) levels following individualized dose titration of asedebart, alongside safety and tolerability assessments, supporting further understanding of direct ACTH neutralization in CD.
The CD study builds on earlier Phase I findings in classic congenital adrenal hyperplasia (CAH) (ClinicalTrials.gov: NCT05669950), which showed pharmacodynamic effects on key adrenal steroid biomarkers. The CD data presented at ENDO add to Lundbeck's evaluation of targeting ACTH-driven endocrine conditions with links to brain function — using early clinical and pharmacodynamic evidence to assess therapeutic potential in areas of significant unmet need.
Asedebart has received Orphan Drug Designation (ODD) for CAH in the European Union and the United States as well as ODD in Japan for the treatment of patients with CD and CAH.
Lu AG22515 data provide insight into CD40L pathway biology
At ENDO, Lundbeck will also present preclinical characterization findings for the investigational CD40L blocker Lu AG22515. CD40L is a key immune signaling molecule heavily implicated in a wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production and in vivo antibody responses.
Additionally, clinical findings will be presented from an exploratory Phase Ib open label study on AG22515 in TED patients. TED is an autoimmune disorder that can cause proptosis, diplopia, pain, disfigurement and, in severe cases, visual impairment or vision loss.4 The presentation will cover three areas: pharmacodynamic assessments designed to evaluate CD40L pathway engagement, safety and tolerability, and preliminary clinical efficacy in TED, including effects on proptosis and other measures of disease activity. The data further enhance the understanding of CD40L pathway modulation in TED and other CD40L-mediated immune disorders.
Asedebart and Lu AG22515 are investigational drugs not approved for marketing by any regulatory authority worldwide, and the efficacy and safety of both molecules have not been established.
Details of Lundbeck presentations at ENDO 2026
Therapeutic Area
Presentation content
Presentation Type
Reference
Cushing's disease
Asedebart
Lu AG13909
A Phase II, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Novel Anti-ACTH Antibody Asedebart in Adults with Cushing's Disease
Oral presentation
Sun 14 June
14:45-15:00 CT
Room W183BC
Thyroid eye disease (TED)
Lu AG22515
Results From a Phase 1b Trial Evaluating CD40-Ligand Blocker Lu AG22515 in Patients with Moderate-to-Severe Thyroid Eye Disease
Oral presentation
Mon 15 June
14:15-14:30 CT
W184ABC
Thyroid eye disease (TED)
Lu AG22515
Preclinical Pharmacokinetic and Pharmacodynamic Profile of Lu AG22515, a CD40-Ligand Blocker in Development for Thyroid Eye Disease
Rapid-fire presentation and poster
Sun 14 June
09:00- 16:00 CT
ENDOExpo;
Poster floor
About Cushing's disease
Cushing's disease is a rare neuro-endocrine disorder caused by a pituitary adenoma that secretes excess ACTH, leading to chronic overproduction of cortisol.1 The condition is associated with significant morbidity and increased mortality, and patients may experience a wide range of physical and neuropsychiatric symptoms.2 First-line treatment is surgical removal of the tumor; however, not all patients are eligible, achieve sustained remission, or benefit fully from current available treatment options, highlighting an ongoing unmet need for effective and well-tolerated therapies.
About asedebart (Lu AG13909)
Asedebart is a humanized anti-ACTH monoclonal antibody designed specifically to recognize ACTH with high affinity. It blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands and thereby inhibits the neurohormonal signalling of ACTH. This inhibition causes a decreased secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands. 5,6 ACTH plays a key role in the biosynthesis of adrenal steroids7 and is therefore considered a promising therapeutic target in conditions characterized by elevated ACTH levels.6
About thyroid eye disease (TED)
Thyroid eye disease (TED) is a rare autoimmune condition associated with thyroid dysfunction, characterized by inflammation and expansion of retro-orbital tissues. Clinical manifestations include proptosis, double-vision, pain, swelling, and disfigurement, and in severe cases may lead to visual impairment or loss of vision. TED can have a substantial impact on daily functioning, quality of life and psychological wellbeing.4
Current treatments are not optimal for all patients and may be associated with significant adverse effects, highlighting the need for additional therapeutic approaches that target underlying autoimmune disease biology. 4
About Lu AG22515
Lu AG22515 is an investigational CD40L blocker being evaluated in CD40L mediated autoimmune diseases. Lu AG22515 is a recombinant fusion protein that binds CD40 ligand (CD40L) and human serum albumin (HSA) to extend half-life. By blocking the interaction between CD40L and the CD40 receptor, Lu AG22515 is designed to modulate a key immune co-stimulatory pathway involved in B-cell activation, antibody responses and inflammatory signaling.
Jens Høyer
Vice President, Head of Investor Relations [email protected]
+45 30 83 45 01
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families, and society as a whole.
Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
References:
Lacroix A, Feelders RA, Stratakis CA, et al. Lancet. 2015;386(9996):913–927Sharma ST, Nieman LK, Feelders RA. Pituitary. 2015;18(2):188–194Ots HD, Tracz JA, Vinokuroff KE, et al. Int J Mol Sci. 2022;23(8):4115Dhaliwal NK, Razzaq L. Cureus. 2025;17(6):e86483.Lundbeck. Data on fileFeldhaus AL, et al. Endocrinology 2017;158(1):1-8Xing Y, et al. J Endocrinol 2011;209(3):327-35CONTACT:
H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311 [email protected]
This information was brought to you by Cision http://news.cision.com
View original content:https://www.prnewswire.com/news-releases/lundbeck-to-present-new-patient-data-on-neuroendocrine-and-neuroimmunology-programs-at-endo-2026-302796359.html
